β-Nicotinamide mononucleotide

SKU: orb1302620

Description

β-Nicotinamide mononucleotide (NMN) is a key biosynthetic precursor to the essential coenzyme NAD+. It is widely used in research to study cellular metabolism, aging, and age-related diseases in both in vitro and in vivo experimental models.

Research Area

Metabolism Research

Key Properties

• CAS Number: 1094-61-7
• MW: 334.22
• Purity: >99.99% (May vary between batches)
• Formula: C₁₁H₁₅N₂O₈P
• SMILES: NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)([O-])=O)[C@@H](O)[C@H]1O
• Target: Endogenous Metabolite
• Solubility: DMSO:Insoluble;H2O:85.8 mg/mL (256.72 mM)

Bioactivity

• In Vivo:
  METHODS: To study the effects on aging, β-nicotinamide mononucleotide (100-300 mg/kg) was administered in drinking water to normally aging wild-type C57BL/6N mice. The administration began at 5 months of age and continued for 12 months until the mice were 17 months old. RESULTS: β-nicotinamide mononucleotide effectively attenuated age-related physiological decline in mice. β-nicotinamide mononucleotide did not have any significant toxic or deleterious effects, inhibited age-related weight gain, enhanced energy metabolism, promoted physical activity, improved insulin sensitivity and lipid levels, and improved insulin resistance. sensitivity and lipid levels, and improved eye function and other pathophysiology.
• In Vitro:
  METHODS: Human corneal epithelial cells HCECs were treated with glucose (25 mM) and β-nicotinamide mononucleotide (5-1000 µM) for 48 h. Cell viability was measured by Trypan blue staining. RESULTS: The effects of different concentrations of β-nicotinamide mononucleotide on HCEC damage induced by high glucose were analyzed. 125, 250 and 500 µM β-nicotinamide mononucleotide showed significant protective effects. METHODS: Late passaged MSCs LP MSCs were treated with β-nicotinamide mononucleotide (100 µM) for 24 h and mitochondrial morphology was analyzed. RESULTS: The mitochondrial staining in LP-MSCs was more diffuse and less intense, while the distribution of mitochondria became concentrated after β-nicotinamide mononucleotide treatment. β-nicotinamide mononucleotide treatment could effectively normalize the mitochondrial morphology and improve the function of mitochondria in senescent MSCs.

Storage & Handling

• Storage: keep away from direct sunlight,store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

βNicotinamide mononucleotide, β-Nicotinamide mononucleotide, β-NM, β Nicotinamide mononucleotide, Alzheimer's, b-Nicotinamide mononucleotide, b-NM, beta-Nicotinamide mononucleotide, beta-NM, cardioprotection, cancer, Endogenous Metabolite, disease, diabetes, inhibit, intermediate, NAD, NMN, obesity, EndogenousMetabolite, Inhibitor

Compound Identifiers

PubChem CID

14180